A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
NCT ID: NCT05303467
Last Updated: 2026-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
36 participants
INTERVENTIONAL
2022-07-30
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
LITT Followed by Hypofractionated RT for Recurrent Gliomas
NCT04181684
Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
NCT02394665
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
NCT04699773
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
NCT02880410
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
NCT07145112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The TheraSphere GBM device utilized in the FRONTIER trial is an yttrium-90 (Y-90) glass microsphere therapy for selective internal radiation therapy (endovascular radiotherapy) in recurrent GBM patients. The TheraSphere GBM treatment utilizes intra-arterial delivery and takes advantage of blood flow and direct tumor delivery. Treatment can be delivered by specific placement of a catheter close to the tumor through known angiographic techniques currently utilized by neuro-endovascular or interventional radiology physicians. Angiographic evaluation prior to treatment allows identification of tumor feeding arteries and definition of the treatment volume. TheraSphere GBM could achieve a high tumor response rate based on delivery of a tumor absorbed dose that is not currently possible with EBRT.
In consideration of the potential benefit of a more localized, targeted treatment with a reduced side effect profile compared to other treatment options, and the potential impact on patients' quality of life for this devastating disease, this First-in-Human Early Feasibility Study (EFS) of the TheraSphere GBM Y-90 Glass Microsphere System for the treatment of recurrent GBM is being conducted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
Enrollment in Group D will not begin until the FDA approves an IDE supplement including all data through the primary safety endpoint from the four Group B subjects, as well as any available data from the Group A and C subjects at the time of submission.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Group A
Subjects in which the perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.
TheraSphere GBM
Single treatment of TheraSphere GBM device
Treatment Group B
Subjects in which the perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.
TheraSphere GBM
Single treatment of TheraSphere GBM device
Treatment Group C
Subjects in which the perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.
TheraSphere GBM
Single treatment of TheraSphere GBM device
Treatment Group D
Subjects in which the perfused volume encompasses the dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.
TheraSphere GBM
Single treatment of TheraSphere GBM device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TheraSphere GBM
Single treatment of TheraSphere GBM device
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Life expectancy ≥ 12 weeks
3. Subject is willing and able to comply with the trial testing, procedures, and follow-up schedule
4. History of a histologically confirmed diagnosis of glioblastoma per 2021 WHO criteria
5. Have radiographic evidence of tumor progression/recurrence with measurable disease (≥ 1 cm to ≤ 5cm bidirectional diameters) by contrast-enhancement on MRI, according to RANO criteria
6. Prior surgery and treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)
7. Prior cranial radiation dose \< 66 Gy
8. WHO performance status ≤ 2
9. The interval since completion of cranial radiotherapy must be \> 6 months, unless there is tissue confirmation of tumor recurrence/progression outside the previous radiation treatment field, in which case the interval since completion of cranial radiation must be at least 12 weeks
10. Interval since last systemic therapy until presumed date of intervention ≥ 1 cycle or ≥ 2 biological half-lives, i.e.
1. ≥ 4 weeks since last dose of temozolomide
2. ≥ 6 weeks since last dose of lomustine or other nitrosourea
3. ≥ 2 weeks since last dose of a small molecule targeted agent (Tyrosine Kinase Inhibitor or similar)
4. ≥ 6 weeks from last dose of last intravenous bevacizumab infusion, or other antibody-based VEGF therapy
11. If receiving steroids, patient should be on a stable or decreasing dose equivalent to dexamethasone ≤ 6 mg/d, for at least 7 days prior to registration
12. Have adequate organ and bone marrow function within 14 days prior to registration, as defined below:
1. INR ≤ 1.2 (in absence of anticoagulation)
2. Platelets ≥ 100,000/L
3. Creatinine ≤1.5 mg/dL
4. Absolute Neutrophil Count ≥1.5 x 10\^9/L
5. Hemoglobin ≥9.0 g/dL
13. Have a negative pregnancy test within 14 days prior to registration on study (for FOCBP, female of child-bearing potential)
14. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically acceptable method of birth control as confirmed by the investigator
1. Accessible neurovascular anatomy that allows for safe microcatheter placement (up to two locations) to infuse TheraSphere GBM to treat all of the T1 enhancing component of target lesion confirmed by neuro-interventional team.
2. Total treatment volume is ≤ 150cc as determined by multidisciplinary team.
1. Group A: perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain
2. Group B: perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain
3. Group C: perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain
4. Group D: perfused volume encompasses the dominant hemisphere and eloquent regions of the brain
Exclusion Criteria
2. Have received more than 1 course of prior cranial radiotherapy (EBRT)
3. Have received radiosurgery, brachytherapy, or hypofractionated radiotherapy
4. Have received more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide
5. Have received prior intra-arterial cerebral infusion therapy
6. Have received more than 2 surgical GBM-related procedures
7. Have received prior thoracic radiation therapy
8. Are at increased risk of wound dehiscence by the discretion of the investigators (e.g. brain surgery within the last 3 months, poor skin condition, and/or previously infected surgical field or any other condition that is of increased infectious risk in the opinion of the neurosurgeon)
9. Have uncontrolled epilepsy
10. Have severe and/or insufficiently controlled intercurrent illness; patients with the following are not eligible:
1. Hypertension grade 3 or higher without adequate control on medications
2. Symptomatic or unstable cardiac disease, known to have right-to-left shunts, or severe pulmonary hypertension (pulmonary artery pressure \> 90 mmHg)
3. Pulmonary insufficiency (arterial oxygen pressure (Pa,O2) of \< 60 mmHg, or oxygen saturation (Sa,O2) of \< 90%) as measured by fingertip pulse oximeter
4. Ongoing or active bacterial or viral infection requiring systemic treatment (including HIV)
5. Pneumonitis
6. Psychiatric illness/social situations that would limit compliance with study requirements
7. Peripheral Neuropathy ≥ grade 1
8. Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety, study endpoints or longevity
11. Are currently pregnant or breast feeding (unless patient agrees to stop breastfeeding)
12. Patients with a history of an active other malignancy within 1 year prior to registration. NOTE: Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease, or recurrent glioblastoma
13. Patients with a history of ischemic cerebral disease and/or at risk of cerebral herniation
14. Medical contraindication to undergo contrast-enhanced magnetic resonance imaging (MRI)
15. Known history of hypersensitivity reactions to iodinated and/or gadolinium-based contrast
16. Subject has received any other investigational agents within 4 weeks of treatment, or is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Scientific Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Riad Salem, M.D.
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Roger Stupp, M.D.
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama Birmingham
Birmingham, Alabama, United States
University of California San Diego
San Diego, California, United States
University of California San Francisco
San Francisco, California, United States
Mayo Jacksonville
Jacksonville, Florida, United States
Northwestern Univerity
Chicago, Illinois, United States
Johns Hopkins Interventional Radiology Center
Baltimore, Maryland, United States
Washington University School of Medicine
St Louis, Missouri, United States
Lenox Hill Hospital
New York, New York, United States
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S2478
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.